The C4 Foundation

C4 Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of medicines called targeted protein degraders. The company utilizes its proprietary TORPEDO platform to design small molecules that harness the body's natural protein recycling system to selectively destroy disease-causing proteins. Their lead clinical programs include CFT7455, an IKZF1/3 degrader for hematologic malignancies, and CFT1946, a BRAF V600E degrader for solid tumors. By targeting proteins previously considered undruggable, C4 Therapeutics aims to provide transformative treatment options for patients with cancer and other difficult-to-treat diseases.